Decreased calcium pump expression in human erythrocytes is connected to a minor haplotype in the ATP2B4 gene

Boglárka Zámbó a, György Várady a, Rita Padányi b, Edit Szabó a, Adrienn Németh a, Tamás Langó a, Ágnes Enyedi b,c, Balázs Sarkadi a,d,

a Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar Tudósok krt. 2, Budapest, 1117, Hungary
b 2nd Department of Pathology, Faculty of Medicine, Semmelweis University, Ullói ut 26., Budapest, 1085, Hungary
c Molecular Oncology Research Group of the Hungarian Academy of Sciences and Semmelweis University, Ullói ut 26., Budapest, 1085, Hungary
d MTA-SE Molecular Biophysics Research Group, Department of Biophysics and Radiation Biology, Semmelweis University, Tuszolto u. 37–43., Budapest, 1084, Hungary

1. Introduction

Plasma membrane Ca2+-ATPases (PMCA) are key calcium exporter proteins in most tissues, and PMCA4b is the main calcium transporter in the human red blood cells (RBCs). In order to assess the expression level of PMCA4b, we have developed a flow cytometry and specific antibody binding method to quantitatively detect this protein in the erythrocyte membrane. Interestingly, we found several healthy volunteers showing significantly reduced expression of RBC-PMCA4b. Western blot analysis of isolated RBC membranes confirmed this observation, and indicated that there are no compensatory alterations in other PMCA isoforms. In addition, reduced PMCA4b levels correlated with a lower calcium extrusion capacity in these erythrocytes. When exploring the potential genetic background of the reduced PMCA4b levels, we found no missense mutations in the ATP2B4 coding regions, while a formerly unrecognized minor haplotype in the predicted second promoter region closely correlated with lower erythrocyte PMCA4b protein levels. In recent GWA studies, SNPs in this ATP2B4 haplotype have been linked to reduced mean corpuscular hemoglobin concentrations (MCHC), and to protection against malaria infection. Our data suggest that an altered regulation of gene expression is responsible for the reduced RBC-PMCA4b levels that is probably linked to the development of human disease-related phenotypes.

© 2017 Elsevier Ltd. All rights reserved.
and in the RBCs the main variant is PMCA4b, while low levels of the PMCA1 protein were also found to be present [1].

Recently we have developed a flow cytometry and antibody based method for the quantitative determination of protein levels in the RBC membrane. This method allows the rapid determination of numerous membrane proteins from a drop of blood (see [6]). Among several, potentially disease-related membrane proteins, we have also routinely determined the level of the relatively abundant RBC membrane PMCA4b protein, as a potential internal control, by using the PMCA4b variant specific JA3 antibody (see Methods). Interestingly, we found several healthy volunteers with significantly lower PMCA4b expression than the average values in the general population. The current report describes the exploration of the genetic background of this phenomenon, with a potential effect on health-related phenotypes.

2. Methods

2.1. RBC membrane protein studies

Blood samples obtained from 155 healthy volunteers were included in these measurements (this research was approved by the Hungarian ethics committee, ETIT). RBC membrane protein determinations were carried out according to our recently developed method [6–9]. In brief, we fixed and permeabilized the RBC membranes by using 1% formaldehyde solution, resulting in RBC “ghosts”, and then equal number of cells were incubated with the PMCA-specific primary antibody (JA3, mouse monoclonal antibody, RRID: AB_628160) followed by a secondary, Alexa Fluor 488 labeled goat anti-mouse (H+L) antibody (Thermo Fisher/Life Technologies), in 96 well plates. We found that in these flow cytometry studies the PMCA4b specific JA3 monoclonal antibody gave the best RBC membrane labeling efficiency, while the JA9 mAb (recognizing both PMCA4 isoforms, RRID: AB_303296) and the 5F10 mAb (recognizing all PMCA variants, RRID: AB_303334) were less efficient. Cellular fluorescence was measured by FACS Canto II flow cytometer, equipped with plate loader.

Isolated human RBC membranes were prepared from 4 mL blood according to the protocol described in [10–12], and Western blots were carried out as described in [13–15]. Equal amounts of protein (determined by Lowry method) were loaded onto 7.5% acrylamide gels, electrophoresed, transferred onto PVDF membranes and immunostained. The following primary antibodies were used: mouse monoclonal antibodies anti-pan PMCA (5F10, RRID: AB_303334, dilution 1:100), anti-PMCA4 (JA9, RRID: AB_303296, dilution 1:250), and anti-PMCA4b (JA3, RRID: AB_628160, dilution 1:1500) and a rabbit polyclonal anti-PMCA1 antibody (NR1, dilution 1:500, [15]). Subsequently, HRP-conjugated anti-mouse or anti-rabbit secondary antibodies (Jackson ImmunoResearch) were applied and detected by Pierce ECL Western Blotting Substrate (Thermo Scientific) and luminography. The ImageJ 1.50i software was used for densitometry analysis.

2.2. Calcium transport measurements in RBCs

The activity of the PMCA in RBCs was analysed by Fluo-4 fluorescence based calcium influx measurements according to Ref. [16], with slight modifications. In brief, intact RBCs were suspended in a high KCl buffer solution (10 mM HEPES, 70 mM NaCl, 80 mM KCl, 10 mM Inosine, 5 mM piruvate, 0.15 mM MgCl₂, 0.1 mM EGTA, pH7.4) and Fluo-4-AM (Molecular Probes/Invitrogen) was added in a final concentrations of 1 μM. RBCs were incubated for 1 h at 37 °C, and then 5 μL of the Fluo-4-loaded RBCs was added to 600 μL of a Ca²⁺ containing medium (10 mM HEPES, 70 mM NaCl, 80 mM KCl, 5 mM Inosine, 5 mM Glucose, 0.15 mM MgCl₂, 150 μM CaCl₂, pH 7.4) buffer on ice. The flow cytometry measurements were started by transferring the samples to room temperature and adding 0.8 μM final concentration of ionomycin (Molecular Probes/Invitrogen), following RBC fluorescence by continuous sampling for 15 min. The area under the curve (AUC) was determined with integral calculation after normalization of the t₀ Fluo-4 fluorescence to zero (OriginPro 8 software).

2.3. Genetic analysis

Genomic DNA was purified from 300 μL of EDTA anticoagulated blood with Puregene Blood Kit (Qiagen). For sequencing the exons and exon-intron boundary regions of the ATP2B4 gene, DNA was amplified by standard PCR method by using the respective primers (see Supplement Table S1). Sanger-sequencing was carried out by the Microsynth Company. TaqMan-based qPCR reactions for SNP detection were carried out in a StepOnePlus device (Applied Biosystems) with premade assay mixes (cat. 4351379) and master mix (cat. 4371353) from Thermo Fisher/Life Technologies. TaqMan probe specificity was verified with sequencing.

3. Results

3.1. PMCA4b protein levels in the RBC membrane

We quantified the level of PMCA4b expression in the RBC membrane of 155 healthy volunteers by flow cytometry (FACS) using the PMCA4b specific JA3 monoclonal antibody. In these experiments we found a number of volunteers with significantly lower than average PMCA expression levels (see Fig. 1A).

In order to confirm these data, the level of PMCA4b expression in the RBC membrane of selected individuals was also determined by Western blotting. This analysis showed similar PMCA expression patterns in all types of samples except that some particular volunteers had a significantly lower PMCA4b protein expression (Fig. 1B), in good correlation with the FACS results. We have also examined if there was a compensatory increase in the PMCA1 protein in the low RBC-PMCA4 membrane samples, but found no significant changes in this respect (see Fig. 1B).

3.2. Decreased expression of the PMCA4b causes reduced calcium extrusion in RBCs

In order to investigate if the reduced PMCA4b protein levels had any significant effect on the calcium homeostasis of the RBCs, we examined the calcium efflux properties of Fluo-4 loaded RBCs after stimulating calcium entry with ionomycin (see Methods and [16]). Fluo-4 loaded RBCs were placed into a medium with a relatively low concentration (150 μM) of Ca²⁺, and then calcium entry was stimulated by the addition of 0.8 μM ionomycin. Using this method we were able to detect the intracellular calcium concentration in real time in live RBCs, and measured the response of the PMCA proteins to the elevated intracellular calcium concentration. Although, PMCAS are the only Ca²⁺ extrusion mechanisms in RBCs (PMCA4b being the most abundant isoform) that could actively eliminate Ca²⁺ from the cytosol [17], multiple ion channels and/or Ca²⁺ buffering proteins may potentially interfere with the assay. The results of three representative experiments in Fig. 1C show that RBCs expressing medium levels of PMCA4b are capable to compensate for the ionophore-induced calcium influx. In contrast, RBCs from volunteers with reduced PMCA4b levels showed reduced ability to compensate for the ionophore-induced rise in cellular calcium, most probably because of the reduced calcium efflux ability of these cells. These results suggest that changes in PMCA4b abundance by itself can effectively influence intracellular calcium levels in RBCs. The calculated area under the curve (AUC) showed

Please cite this article in press as: B. Zámbo, et al., Decreased calcium pump expression in human erythrocytes is connected to a minor haplotype in the ATP2B4 gene, Cell Calcium (2017), http://dx.doi.org/10.1016/j.c cea.2017.02.001
that RBCs with low PMCA4b abundance (AUC[K007] = 7.56 ± 0.33 and AUC[K172] = 7.99 ± 2.75) have an about 1.58–1.67 fold higher overall Ca²⁺ levels, compared to that in the control RBCs with average level of PMCA4b (AUC[K030] = 4.79 ± 0.37). Thus, a reduced PMCA4b level may directly impair calcium homeostasis in the RBCs of these otherwise healthy volunteers.

### 3.3. A minor haplotype in the ATP2B4 gene correlates with decreased PMCA4b protein expression

RBC membrane protein levels may be affected by direct genetic alterations or by various regulatory modulations (see [6,9]). According to our previous experience, strongly reduced RBC expression levels of the ABCG2 [7] and the ABCB6 [8] membrane proteins were connected to specific mutations and/or polymorphisms in the coding genes. Therefore, we analyzed the DNA extracts of the blood samples of the volunteers with low RBC-PMCA4b expression by Sanger sequencing of the ATP2B4 gene, coding for this protein. The sequencing primers were selected to screen all exons and exon-intron boundaries of the ATP2B4 gene.

When sequencing the ATP2B4 genes of individuals with reduced RBC-PMCA4b protein levels (K007 and K076) we did not find any mutations or polymorphisms in the coding regions. In contrast, we
Fig. 2. Haplotypes in the ATP2B4 gene and their correlation with the level of PMCA4b expression in the red blood cells of healthy volunteers.
(A) Haplotype/SNP localizations in the ATP2B4 gene. The two isoforms of the PMCA4 protein, 4a and 4b, which are different in their C-terminal regulatory regions, result from alternative transcript variants. (B) Left side: Relative expression levels of RBC-PMCA4b (155 samples) and the respective Haplotypes – lower PMCA4b protein levels in the RBCs are closely correlated with the presence of the minor variant of Haplotype 1.
Minor allele homozygotes: red, minor allele heterozygotes: yellow, major alleles: green. Right side: Mean values ± SD values (at least two independent parallels), of the PMCA4b expression levels versus the ATP2B4 genotypes (Kruskal-Wallis tests).
found 7 SNPs in heterozygous forms in the non-coding regions of these samples, which were not present in samples with medium RBC-PMCA4b expression (K014, K030, K048, K077) (Fig. 2A).

When further sequencing the DNA from individuals with very low RBC-PMCA4b expression levels (K110, K172) we found that the first 5 SNPs were present in a homozygous form, and the other two SNPs were either homozygous (K110) or heterozygous (K172). According to the LDLink data (NIH NCBI, [18]) all these five SNPs (rs1541252, rs1541253, rs377342347, rs1419114, rs2228445) and the other two SNPs (rs955865, rs955866) are inherited together in haplotypes (termed here by us as Haplotype 1 and Haplotype 2).

Haplotype 1 is in the 5‘ region of the gene, between intron 1 to exon 3, and a proxy analysis of rs1419114 revealed that there are more than 50 short variants (including insertions and deletions) in this formerly unrecognized Haplotype, in a complete linkage disequilibrium (R² = 0.9, LDLink database). The minor allele frequency of the variants in this haplotype 1 in Europe is about 0.11 (NCBI SNP database). In case of Haplotype 2, proxy analysis showed that about 9 variants are inherited together (R² > 0.9), but there are some other SNPs in the exon 20 and 3’UTR region of the gene which show slight linkage disequilibrium (0.9 > R² > 0.2) with these variants. The minor allele frequency of Haplotype 2 in Europe is about 0.44 (NCBI SNP database). Interestingly, Haplotype 1 and 2 are in a weak linkage disequilibrium (Pearson correlation coefficient R² = 0.1505), and rs2228445 in Haplotype 1 shows high regulomeDB score (2b in LDLink), and relatively high R² coefficient in proxy search with Haplotype 2 (R² = 0.1214). These data suggest that SNP rs2228445 is a member of both haplotypes, and has a potential role in regulating membrane protein levels.

In addition, we have sequenced the coding region of the ATP2B4 gene in individuals showing higher RBC-PMCA4b expressions than average (K195, K005, K006). Studying these sequences we observed another haplotype (rs3753036, Haplotype 3), which overlaps the first haplotype, and an SNP (rs4600103), which is a variant at the first exon of the gene. Haplotype 3 contains at least 36 more variants in linkage disequilibrium (R² > 0.9), with a minor allele frequency of 0.18 (NCBI database). The exon 1 variant shows weak (R² = 0.8) linkage disequilibrium with other SNPs close to its region in chromosome 1. The minor allele frequency of this exon 1 SNP is around 0.13 in the European population. It is important to note that none of these variants in the respective haplotypes cause any change in the amino acid sequence of the PMCA4 protein, most of them are in the intronic or UTR regions of the gene. The locations of the Haplotype 1–3 and the exon 1 SNP in the ATP2B4 gene region are shown in Fig. 2A.

In the following experiments we analyzed the potential correlation of Haplotypes 1–3 with the RBC-PMCA4b levels. For this purpose we set up a TaqMan assay to screen a total of 155 blood samples, in which we already had the flow cytometry data for PMCA4b expression. We chose the rs1541252 (Haplotype 1), rs955866 (Haplotype 2), rs3753036 (Haplotype 3) as tagging SNPs to detect Haplotype 1, 2, and 3, respectively, and examined the SNP in exon 1 of the gene (rs4600103) as well.

The obtained results clearly show that the reduced RBC-PMCA4b protein levels correlate with the presence of the minor allele in Haplotype 1 (rs1541252 C>T, p < 0.001, Fig. 2B, Table 1). The second (rs955866 C>T) and third (rs3753036 G>A) haplotypes were only weakly related to the PMCA4b protein levels, probably because Haplotype 2 shows a weak linkage disequilibrium with Haplotype 1 (Pearson correlation coefficient R² = 0.1505), and Haplotype 3 overlaps Haplotype 1 (Fig. 2A). The SNP in exon 1 did not show any significant correlation with the PMCA4b protein levels. The presence of the minor Haplotype 1 in a heterozygous (CT) form reduced RBC-PMCA4b expression by about 25%, while in a homozygous (TT) form this minor Haplotype caused a 50% expression reduction (Table 2). The Haplotype variants showed a Hardy-Weinberg equilibrium (Haplotype 1: p = 0.9900, Haplotype 2: p = 0.9113, Haplotype 3: p = 0.4163, rs4600103: p = 0.9999, with Chi-square tests), the respective MAFs (minor allele frequencies) were q(T) = 0.0165, q(T) = 0.4161, q(A) = 0.1806, q(A) = 0.1129, in our sample set (155 samples of healthy individuals, Table 1). We successfully validated these results with a Sanger-sequencing of the affected ATP2B4 regions in further 22 blood samples.

### 4. Discussion

In this study we found that PMCA4b expression, as measured by a flow cytometry method in the RBCs of healthy donors, showed a relatively constant average level, while in some donor RBCs the level of this transporter protein was much lower. We confirmed the lower PMCA4b expression levels by Western blotting in the respective isolated RBC membranes, and showed that the lower PMCA4b expression caused an impaired calcium efflux from the RBCs.

The localization and function of integral plasma membrane proteins, such as the PMCA4b protein, may be modulated by numerous factors, including transcriptional and translational regulation, protein trafficking or membrane lipid compositions. Since PMCA4s are not glycosylated, and the plasma membrane is the only membrane compartment in RBCs, the most plausible explanation for the reduced RBC-PMCA4b expression is a translational regulation. When examining the potential genetic background of the relatively low RBC-PMCA4b expression, we found no alterations in the coding regions that could result in amino acid changes, or altered splicing sequences in the ATP2B4 gene, coding for this protein. Regarding the intrinsic and potential regulatory regions, our sequencing experiments showed a large number of variable SNPs, potentially involved in generating these changes in the protein expression level. We examined the correlation of three haplotypes in the ATP2B4 gene with the protein expression, and found that the minor allele of a formerly unrecognized Haplotype 1 strongly correlates with low PMCA4b expression, namely heterozygotes show about 25%, while...

---

Please cite this article in press as: B. Zámbo, et al., Decreased calcium pump expression in human erythrocytes is connected to a minor haplotype in the ATP2B4 gene, Cell Calcium (2017), http://dx.doi.org/10.1016/j.ceca.2017.02.001
homozygotes show about 50% of reduction of PMCA4b in the RBC membrane.

According to the Eukaryotic Promoter Database (EPDnew, [19]), there are two putative promoters in the 1TP2B4 gene. The first promoter is located at around the first exon, the second promoter is around the second exon, corresponding to Haploype 1, shown here to affect PMCA4b expression. Our data suggest that SNPs in Haploype 1 alter the binding of transcription factors which promote PMCA4b protein expression in myeloid blood cell differentiation, thus in RBC generation. Based on the PROMO (Aligeren, [20]) database, the SNPs in Haploype 1 may alter the binding sites for a large number of transcription factors, including GATA-1 and c-Myc, preferentially expressed in hematopoietic lineages. Further detailed studies are required to examine the role of the actual transcription factor binding sites in this region to regulate PMCA4 expression.

Haploype 2 is located in the 3´ UTR of the 1TP2B4 gene and shows weak correlation (R² = 0.1505) with Haploype 1, which may indicate an initial evolutionary assembly into a common haplotype. Haploype 3 shows a partially overlapping location with Haploype 1 (Fig. 2), and the minor allele of Haploype 3 has a weak, but statistically significant effect to increase PMCA4b expression levels.

Haploype 1 is located in a common region of the splice variants of the 1TP2B4 gene, coding both for PMCA4b and PMCA4a, thus Haploype 1 may affect the expression regulation of both PMCA4 isotypes. Since it is difficult to obtain various human tissue samples for measuring quantitative PMCA4 expression levels, currently we do not know if the observed changes in the membrane PMCA levels are restricted to the RBCs or may affect the expression level of this protein in other tissues as well. Still, a potential correlation of the expression regulation of PMCA4 with disease phenotypes is a challenging question.

The PMCA4 protein is a key calcium transporter in various signaling and regulatory events. Specifically PMCA4 and PMCA1 were shown to be involved in osteoclast function; the altered expression of these PMCA isoforms would thus affect the bone mass of menopausal women [21]. PMCA4a is the major calcium transporter protein in the human sperm and has an essential role in the motility of these cells, hence reduced PMCA4a might be involved in male sterility [23].

Several recent studies found potential associations between SNPs in the ATP2B4 gene, and diseases or disease-related conditions, including reduced bone mass [21], increased incidence of schizophrenia [22], cardiac hypertrophy [23], red blood cell traits [24], and the incidence of malaria infection [25]. In GWAS studies the SNP rs7551442 in the ATP2B4 gene was specifically linked to red blood cell MCHC (mean corpuscular hemoglobin concentration, Ref. [24]), while SNPs rs2365860, rs10906058, rs2365858 and rs4951074 were linked to malaria infection sensitivity [25]. These conditions may be linked phenotypes, e.g. impaired calcium pump activity in the myeloid progenitors may result in reduced RBC hemoglobin concentrations, altered cell shape and size, and in the mature RBCs may reduce Plasmodium infection. Plasmodium infection causes malaria, hence a reduction in Plasmodium infection may protect from, or ameliorate malaria. Interestingly, all these above SNPs found in the GWAS studies, are localized and thus inherited together, within a formerly unrecognized haplotype 1 of 1TP2B4.

Plasmodium malariae prolarlates in the erythrocytes, where the parasite matures and multiplies within the parasitophorous vacuole (PV). This membrane vacuole is an invagination of the RBC plasma membrane, which contains the proteins of the host erythrocyte, including PMCA4b. Recent studies [26,27] suggest that the parasite growth needs a sufficiently high calcium level in the PVs, and while the Ca²⁺ in the RBC cytoplasm is very low, it is much higher (~40 µM) within the PVs. Since PMCA4b is present in an inverted situation in the PV membrane, it pumps Ca²⁺ into the PV, thus generating the high Ca²⁺ microenvironment for the parasite. Therefore, individuals carrying the ATP2B4 haplotype with a reduced level of PMCA4b may be protected against malaria due to a lower calcium level in the PV, causing reduced proliferation of the parasite.

Here we document a major reduction of this calcium transporter protein in the RBCs of individuals carrying the minor variant of Haploype 1. Our studies thus establish a strong correlation between the gene-regulation based changes in membrane PMCA levels and the development of human disease-related phenotypes.

Based on this study, we further emphasize the advantages of the direct measurements of RBC membrane proteins in discovering genetic regulatory effects, and their potential in future personalized diagnostic approaches.

Competing interests

We have no conflict of interest to report.

Author contributions

Contributions: B.Z. designed and performed the experiments, analyzed the data; G.Y. developed the antibody based FACS method, G.Y., E.S., A.N. and B.Z. performed and analysed the antibody based FACS measurement; R.P. and A.E. designed the Western-blot and R.P. performed the Western-blot measurements; T.L. and B.Z. performed the isolation of RBC membrane; A.E. and B.S. designed the concept of the study, analyzed the data; B.Z. and B.S. wrote the manuscript. All authors reviewed the manuscript.

Acknowledgements

We greatly appreciate the advice and help of Michael Dean, NIH, USA, in analyzing the SNP databases, and the technical assistance by Krisztina Lőr. This study has been supported by grants from NKFIH (K115375, FIKK16 to BS; and ANN110922, K119223 to AE).

References

[9] G. Varady, J. Cserpe, A. Németh, E. Szabó, B. Sarkadi, Cell surface membrane proteins as personalized biomarkers: where we stand and where we are


Please cite this article in press as: B. Zámbo et al., Decreased calcium pump expression in human erythrocytes is connected to a minor haplotype in the ATP2B4 gene, Cell Calcium (2017), http://dx.doi.org/10.1016/j.ceca.2017.02.001